Inhibikase TherapeuticsIKT
13F holders, Q1 2024 (March 31)12holders
1famous investor
$2.16avg. 13F price*
At the end of Q1 2024, 12 institutions reported holding Inhibikase Therapeutics Inc. (IKT) in their 13F filings. The largest holders were Blair William & Co. ($165K), Geode Capital Management, LLC ($62K) and Susquehanna International Group, LLP ($49K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Inhibikase Therapeutics Inc.
- CUSIP
- 45719W205
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $60K |
| Exits | 2 | $3K |
Ownership 12 holders
| Blair William & Co. | 0.00% | Add +27.1% | 76,601 | $165K |
| Geode Capital Management, LLC | 0.00% | No change | 28,692 | $62K |
| Susquehanna International Group, LLP | 0.00% | New | 22,616 | $49K |
| Renaissance Technologies | 0.00% | Reduce -12.3% | 21,422 | $46K |
| Redmond Asset Management, LLC | 0.01% | Reduce -0.4% | 19,560 | $42K |
| Vanguard Group Inc. | 0.00% | Reduce -79.6% | 16,724 | $36K |
| State Street Corp. | 0.00% | No change | 10,084 | $22K |
| UBS Group AG | 0.00% | New | 3,214 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -53.2% | 2,771 | $6K |
| Osaic Holdings, Inc. | 0.00% | New | 2,000 | $4K |
| Morgan Stanley | 0.00% | No change | 1,667 | $4K |
| Wells Fargo & Company | 0.00% | Add +3.0% | 207 | $447 |
"% of holder's portfolio" is IKT's weight in each manager's 13F, not the share of Inhibikase Therapeutics Inc. the manager owns.